Manuel Carrondo

Manuel Carrondo is Full Professor of Chemical and Biochemical Engineering at the Faculty of Sciences and Technology at NOVA University of Lisbon (retired).

He has extensive management experience in the biotechnology sector and is iBET’s vice-president for Business Development. His key areas of interest include (i) Animal Cell Technology and its application for human and animal health, (ii) therapeutic and diagnostic recombinant proteins, including fusion proteins, (iii) virus-like particles and pseudo viruses as vaccination agents and viruses (retro-, adeno-, lenti-) as deliverables for gene therapy, (iv) cell therapies and stem cells and (v) cGMP pilot plant scale-up and production development of biopharmaceuticals.

Manuel has been Advisory Board Member of CEVEC Pharmaceuticals, PBS Biotech, CNIC (Spanish National Center for Cardiovascular Research Carlos III), Masthercells (Manufacturing Synergies for Therapeutic Cells), Alloksys Life Sciences BV, IBMT (Fraunhofer Institute for Biomedical Engineering), Max-Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, KGI-Keck Graduate Institute, Claremont, California and GenIbet Biopharmaceuticals, Portugal.

Manuel was also the Portuguese representative to the Working Party on Biotechnology, Nanotechnology and Converging Technologies of OECD (2014-2018) and chairman of European Society of Animal Cell Technology (ESACT) from 1997-2001, currently honorary member. Manuel was a Visiting Professor at Carnegie-Mellon University (1981), Massachusetts Institute of Technology – MIT (1988), Gesellschaft für Biotechnologische Forschung (1989 and 1993).

Manuel has published over 250 papers, 22 book chapters and supervised 35 PhD students.